Temporal Immunologic Changes With Hypofractionated Radiation-Induced DNA Damage in Breast Cancer
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorM.D. Anderson Cancer Center
About this trial
This study assesses changes to the immune cells following hypofractionated radiation-induced DNA damage in breast cancer patients. Radiation therapy may cause immune cells to enter tumors and target cancer cells. The goal of this study is to measure the change in the level of immune cells in the tumor before and after radiation therapy.
Eligibility criteria
Qualifiers
Patients >= 18 years of age with biopsy proven invasive breast cancer
Breast cancer that appears to be superficially accessible to a tumor punch biopsy
Patients thought to derive clinical benefit from palliative RT to the breast/chestwall
In discussions with the medical oncologist, if clinically reasonable, systemic therapy will be held during RT
Disqualifiers
A history of prior radiation to the area requiring radiation for which the attending physician believes reirradiation could not be safely delivered
Pregnancy
Active usage of anticoagulant medications that are considered to pose an increased risk of tumor punch biopsies
Receipt of immunotherapy or chemotherapy 7 days prior to start of RT
Trial design
Treatments tested in this trial
- Biopsy
- Biospecimen Collection
- Radiation Therapy
Treatment groups
36 Participants
are divided into 1 treatment groupSponsors and collaborators
M.D. Anderson Cancer Center
Lead sponsor
Artidis
Collaborator
Source ClinicalTrials.gov